Diabetic nephropathy is resistant to oral L-arginine or L-citrulline supplementation

American Journal of Physiology - Renal Physiology

Volumn 307, Issue 11, 2014, Pages F1292-F1301

  You, Hanning ^a   Gao, Ting ^a   Cooper, Timothy K ^a   Morris, Sidney M ^b   Awad, Alaa S ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Diabetic nephropathy; L arginine; L citrulline; Oral supplementation

Indexed keywords

ALBUMIN; AMINO ACID; ARGINASE; ARGININE; CITRULLINE; CREATININE; DRINKING WATER; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FIBRONECTIN; NEPHRIN; NITRATE; NITRIC OXIDE; NITRITE; STREPTOZOCIN; TUMOR NECROSIS FACTOR ALPHA; MEMBRANE PROTEIN; NITRIC ACID DERIVATIVE;

ALBUMINURIA; AMINO ACID BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIET SUPPLEMENTATION; ENZYME ACTIVITY; ENZYME MECHANISM; GENE EXPRESSION; GLOMERULUS FILTRATION RATE; HISTOPATHOLOGY; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY PARENCHYMA; MACROPHAGE; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RENAL PROTECTION; TISSUE LEVEL; UREA NITROGEN BLOOD LEVEL; ANIMAL; BIOSYNTHESIS; BLOOD; BLOOD PRESSURE; DBA MOUSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; KIDNEY; METABOLISM; PATHOLOGY; PHYSIOLOGY;

AMINO ACIDS; ANIMALS; ARGINASE; ARGININE; BLOOD PRESSURE; CITRULLINE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DIETARY SUPPLEMENTS; FIBRONECTINS; KIDNEY; MALE; MEMBRANE PROTEINS; MICE; MICE, INBRED DBA; NITRATES; NITRIC OXIDE SYNTHASE TYPE III; NITRITES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84913534387     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00176.2014     Document Type: Article

References (39)

1. Awad AS, Gao T, Gvritishvili A, You H, Liu Y, Cooper TK, Reeves WB, Tombran-Tink J. Protective role of small pigment epithelium-derived factor (PEDF) peptide in diabetic renal injury. Am J Physiol Renal Physiol305: F891–F900, 2013.
2. Awad AS, Huang L, Ye H, Duong ET, Bolton WK, Linden J, Okusa MD. Adenosine A2A receptor activation attenuates inflammation and injury in diabetic nephropathy. Am J Physiol Renal Physiol290: F828–F837, 2006.
3. Bai Y, Sun L, Yang T, Sun K, Chen J, Hui R. Increase in fasting vascular endothelial function after short-term oral L-arginine is effective when baseline flow-mediated dilation is low: a meta-analysis of randomized controlled trials. Am J Clin Nutr89: 77-84, 2009.
4. Balakumar P, Chakkarwar VA, Krishan P, Singh M. Vascular endothelial dysfunction: a tug of war in diabetic nephropathy? Biomed Phar-macother63: 171-179, 2009.
5. Beleznai T, Feher A, Spielvogel D, Lansman SL, Bagi Z. Arginase 1 contributes to diminished coronary arteriolar dilation in patients with diabetes. Am J Physiol Heart Circ Physiol300: H777-H783, 2011.
6. Boger RH. L-Arginine therapy in cardiovascular pathologies: beneficial or dangerous? Curr Opin Clin Nutr Metab Care11: 55-61, 2008.
7. Breyer MD, Bottinger E, Brosius FC, 3rd Coffman TM, Harris RC, Heilig CW, Sharma K. Mouse models of diabetic nephropathy. J Am Soc Nephrol16: 27-45, 2005.
8. Brodsky SV, Gao S, Li H, Goligorsky MS. Hyperglycemic switch from mitochondrial nitric oxide to superoxide production in endothelial cells. Am J Physiol Heart Circ Physiol283: H2130-H2139, 2002.
9. Brosius FC 3rd, Alpers CE, Bottinger EP, Breyer MD, Coffman TM, Gurley SB, Harris RC, Kakoki M, Kretzler M, Leiter EH, Levi M, McIndoe RA, Sharma K, Smithies O, Susztak K, Takahashi N, Takahashi T. Mouse models of diabetic nephropathy. J Am Soc Nephrol20: 2503-2512, 2009.
10. Castillo L, Chapman TE, Yu YM, Ajami A, Burke JF, Young VR. Dietary arginine uptake by the splanchnic region in adult humans. Am J Physiol Endocrinol Metab265: E532-E539, 1993.
11. Chen C, Mitchell KD, Navar LG. Role of endothelium-derived nitric oxide in the renal hemodynamic response to amino acid infusion. Am J Physiol Regul Integr Comp Physiol263: R510-R516, 1992.
12. Closs EI, Simon A, Vekony N, Rotmann A. Plasma membrane transporters for arginine. J Nutr 134: 2752S-2759S and 2765S-2767S, 2004.
13. Creager MA, Luscher TF, Cosentino F, Beckman JA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Circulation108: 1527-1532, 2003.
14. Giunti S, Barutta F, Perin PC, Gruden G. Targeting the MCP-1/CCR2 system in diabetic kidney disease. Curr Vasc Pharmacol8: 849-860, 2010.
15. Goligorsky MS, Chen J, Brodsky S. Workshop: endothelial cell dysfunction leading to diabetic nephropathy: focus on nitric oxide. Hypertension37: 744-748, 2001.
16. Hyndman KA, Boesen EI, Elmarakby AA, Brands MW, Huang P, Kohan DE, Pollock DM Pollock JS. Renal collecting duct NOS1 maintains fluid-electrolyte homeostasis and blood pressure. Hypertension62: 91-98, 2013.
17. Jim B, Ghanta M, Qipo A, Fan Y, Chuang PY, Cohen HW, Abadi M, Thomas DB, He JC. Dysregulated nephrin in diabetic nephropathy of type 2 diabetes: a cross sectional study. PLOS ONE7: e36041, 2012.
18. Kalantarinia K, Awad AS, Siragy HM. Urinary and renal interstitial concentrations of TNF-a increase prior to the rise in albuminuria in diabetic rats. Kidney Int64: 1208-1213, 2003.
19. Kohli R, Meininger CJ, Haynes TE, Yan W, Self JT, Wu G. Dietary L-arginine supplementation enhances endothelial nitric oxide synthesis in streptozotocin-induced diabetic rats. J Nutr134: 600-608, 2004.
20. Lapenna D, Ciofani G, Pierdomenico SD, Giamberardino MA, Cuc-curullo F. Reaction conditions affecting the relationship between thiobar-bituric acid reactivity and lipid peroxides in human plasma. Free Radic Biol Med31: 331-335, 2001.
21. Lu D, Fu Y, Lopez-Ruiz A, Zhang R, Juncos R, Liu H, Manning RD Jr, Juncos LA, Liu R Salt-sensitive splice variant of nNOS expressed in the macula densa cells. Am J Physiol Renal Physiol298: F1465-F1471, 2010.
22. Morris SM Jr. Arginine metabolism: boundaries of our knowledge. J Nutr137: 1602S-1609S, 2007.
23. Morris SM Jr, Gao T, Cooper TK, Kepka-Lenhart D, Awad AS. Arginase-2 mediates diabetic renal injury. Diabetes60: 3015-3022, 2011.
24. Romero MJ, Yao L, Sridhar S, Bhatta A, Dou H, Ramesh G, Brands MW, Pollock DM, Caldwell RB, Cederbaum SD, Head CA, Bagi Z, Lucas R, Caldwell RW. L-Citrulline protects from kidney damage in type 1 diabetic mice. Front Immunol4: 480, 2013.
25. Schwedhelm E, Maas R, Freese R, Jung D, Lukacs Z, Jambrecina A, Spickler W, Schulze F, Boger RH. Pharmacokinetic and pharmacodynamic properties of oral L-citrulline and L-arginine: impact on nitric oxide metabolism. Br J Clin Pharmacol65: 51-59, 2008.
26. Tang WW, Qi M, Warren JS. Monocyte chemoattractant protein 1 mediates glomerular macrophage infiltration in anti-GBM Ab GN. Kidney Int50: 665-671, 1996.
27. Tipping PG, Leong TW, Holdsworth SR. Tumor necrosis factor production by glomerular macrophages in anti-glomerular basement membrane glomerulonephritis in rabbits. Lab Invest65: 272-279, 1991.
28. Tipping PG, Lowe MG, Holdsworth SR. Glomerular interleukin 1 production is dependent on macrophage infiltration in anti-GBM glomer-ulonephritis. Kidney Int39: 103–110, 1991.
29. Topal G, Brunet A, Walch L, Boucher JL, David-Dufilho M. Mito-chondrial arginase II modulates nitric-oxide synthesis through nonfreely exchangeable L-arginine pools in human endothelial cells. J Pharmacol Exp Ther318: 1368–1374, 2006.
30. United States Renal Data System. Annual Data Report (online). http:// www.usrds.org/atlas07.aspx [20 October 2014].
31. Wada T, Furuichi K, Sakai N, Iwata Y, Yoshimoto K, Shimizu M, Takeda SI, Takasawa K, Yoshimura M, Kida H, Kobayashi KI, Mukaida N, Naito T, Matsushima K, Yokoyama H. Up-regulation of monocyte chemoattractant protein-1 in tubulointerstitial lesions of human diabetic nephropathy. Kidney Int58: 1492–1499, 2000.
32. Wang CH, Li F, Hiller S, Kim HS, Maeda N, Smithies O, Takahashi N. A modest decrease in endothelial NOS in mice comparable to that associated with human NOS3 variants exacerbates diabetic nephropathy. Proc Natl Acad Sci USA108: 2070–2075, 2011.
33. Windmueller HG, Spaeth AE. Metabolism of absorbed aspartate, aspar-agine, and arginine by rat small intestine in vivo. Arch Biochem Biophys175: 670–676, 1976.
34. Xia Y, Dawson VL, Dawson TM, Snyder SH, Zweier JL. Nitric oxide synthase generates superoxide and nitric oxide in arginine-depleted cells leading to peroxynitrite-mediated cellular injury. Proc Natl Acad Sci USA93: 6770–6774, 1996.
35. Yamamizu K, Shinozaki K, Ayajiki K, Gemba M, Okamura T. Oral administration of both tetrahydrobiopterin and L-arginine prevents endo-thelial dysfunction in rats with chronic renal failure. J Cardiovasc Pharmacol49: 131–139, 2007.
36. You H, Gao T, Cooper TK, Brian Reeves W, Awad AS. Macrophages directly mediate diabetic renal injury. Am J Physiol Renal Physiol305: F1719–F1727, 2013.
37. You H, Gao T, Cooper TK, Morris SM Jr, Awad AS. Arginase inhibition mediates renal tissue protection in diabetic nephropathy by a nitric oxide synthase 3-dependent mechanism. Kidney Int84: 1189–1197, 2013.
38. Zhang A, Huang S. Progress in pathogenesis of proteinuria. Int J Nephrol 2012: 314251.
39. Zhao HJ, Wang S, Cheng H, Zhang MZ, Takahashi T, Fogo AB, Breyer MD, Harris RC. Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in diabetic mice. J Am Soc Nephrol17: 2664–2669, 2006.